On February 15th, 2022, the European Commission (EC) declared CBDepot鈥檚 Novel Food application NF 2021/2283 for isolated聽trans-Cannabidiol as valid. This sets the number of CBDepot鈥檚 valid Novel Food applications with EC and FSA to four.
CBDepot鈥檚 commitment to Novel Food compliance began in early 2016, shortly after Cannabis Pharma launched the CBDex庐 brand. CBDepot鈥檚 EU application NF 2019/1371 was the first-ever CBD-specific dossier to have reached validation on March 27th, 2020. The NF2019/1371 covers synthesized trans-Cannabidiol.
In early January 2021, CBDepot filed two Regulated Product applications with the UK FSA to grant access for its two grades of Cannabidiol to the most significant legal CBD food supplement market worldwide: application RP70, for Synthesized Cannabidiol with 4MP庐- branded secondary products in the forms of carrier oils, measured dose spray, and chewable tablets, and application RP85, for Isolated Cannabidiol and CBDex庐-branded secondary products in the form of carrier oils linked to this dossier. In April 2021, both RP70 and RP85 were declared valid by UK FSA.
鈥淗aving four validated applications out of four submitted and appearing on the shortlist of the few validated applications, confirms CBDepot鈥檚 position as the leader in the compliant, upmarket cannabinoid sector,鈥� stresses Boris Ba艌as group鈥檚, Chief Sales Officer.